Drug Findings, Applications and Approvals Strengthen Prospects - Research Report on Health Management Associates, Boston Scientific, Endo Health, Achillion Pharmaceuticals, and Cardiovascular Systems

NEW YORK, June 5, 2013 /PRNewswire/ --

Editor Note: For more information about this release, please scroll to bottom.

Today, Wall Street Reports announced new research reports highlighting Health Management Associates Inc. (NYSE: HMA), Boston Scientific Corporation (NYSE: BSX), Endo Health Solutions Inc. (NASDAQ: ENDP), Achillion Pharmaceuticals, Inc. (NASDAQ: ACHN), and Cardiovascular Systems Inc. (NASDAQ: CSII). Today's readers may access these reports free of charge - including full price targets, industry analysis and analyst ratings - via the links below.

Health Management Associates Inc. Research Report

On May 28, 2013, Health Management Associates Inc.'s (Health Management Associates) Board of Directors announced that Gary D. Newsome will retire as President, Chief Executive Officer and Member of the Board of Directors, effective July 31, 2013. According to the Company, Mr. Newsome has been called by the First Presidency of the Church of Jesus Christ of Latter-day Saints to serve as the President of its Uruguay-Montevideo Mission in South America. The Company affirmed that Mr. Newsome will continue to lead the Company until his retirement. Directors Kent P. Dauten, Donald E. Kiernan, Robert A. Knox, and William J. Schoen will lead the search for a new Chief Executive Officer. The Full Research Report on Health Management Associates Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.wsreports.com/r/full_research_report/96e5_HMA]

--

Boston Scientific Corporation Research Report

On May 27, 2013, Boston Scientific Corporation (Boston Scientific) announced that it has received CE Mark approval for use of the GUIDE DBS System, the world's first deep brain stimulation (DBS) visualization system. GUIDE DBS creates 3D visualization information that simulates stimulation output, which may reduce programming time and enable more precise therapies. Combined with the Vercise DBS System, the GUIDE DBS can provide the most advanced deep brain stimulation technology to neurologists, neurosurgeons, and their patients. Both, the GUIDE DBS and the Vercise DBS, are CE Marked for the treatment of Parkinson's disease. The Vercise DBS System was approved for sale in Europe in 2012. The Full Research Report on Boston Scientific Corporation - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.wsreports.com/r/full_research_report/5649_BSX]

--

Endo Health Solutions Inc. Research Report

On May 30, 2013, Endo Pharmaceuticals, Inc. (Endo Pharmaceuticals), a subsidiary of Endo Health Solutions, Inc. (Endo Health Solutions) announced that the U.S. Food and Drug Administration (FDA) issued a complete response letter regarding the New Drug Application (NDA) for Endo's long-acting testosterone undecanoate injection, AVEED, for men diagnosed with hypogonadism. According to the Company, the FDA outlined the necessary steps to support the approval of the NDA and requested that the Risk Evaluation and Mitigation Strategy (REMS) include a Medication Guide as well as Elements to Assure Safe Use (ETASU) to mitigate risks and severe complications related to post-injection reactions. However, the complete response letter did not include requests for the Company to perform additional clinical studies. Endo Pharmaceuticals plans to submit a complete response by the end of Q3 2013. The Full Research Report on Endo Health Solutions Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.wsreports.com/r/full_research_report/0e90_ENDP]

--

Achillion Pharmaceuticals, Inc. Research Report

On May 30, 2013, Achillion Pharmaceuticals, Inc. (Achillion Pharmaceuticals) announced the nomination of the preclinical compound, ACH-3422, a novel small molecule nucleotide prodrug of a uridine analog designed to inhibit HCV NS5B polymerase. This compound will be used as a development candidate for the treatment of chronic hepatitis C (HCV) viral infection. Milind Deshpande, Ph.D., Achillion Pharmaceuticals' President and Chief Executive Officer, said, "The addition of ACH-3422 gives Achillion a portfolio of assets that also includes a 2nd generation protease inhibitor, sovaprevir, and a 2nd generation NS5A inhibitor, ACH-3102, which together provide Achillion the opportunity to potentially optimize treatment outcomes and duration of therapy across all HCV patients." The Company plans to complete regulatory submissions in Q1 2014, with first in-human studies anticipated in the first half of 2014, followed by combination development in the second half of 2014. The Full Research Report on Achillion Pharmaceuticals, Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.wsreports.com/r/full_research_report/0fa0_ACHN]

--

Cardiovascular Systems Inc. Research Report

On May 30, 2013, Cardiovascular Systems, Inc. (Cardiovascular Systems) announced that the first patient has been enrolled in its post-market study, LIBERTY 360. The study evaluates the acute and long-term clinical and economic outcomes of CSI's orbital atherectomy system in treating peripheral arterial disease (PAD). It is also the first study of its kind to compare orbital atherectomy to all other PAD treatment options in a difficult-to-treat population. David L. Martin, CSI President and Chief Executive Officer, said, "Past studies have proven that treating PAD patients with our orbital atherectomy system is safe and effective. The LIBERTY 360 study is a massive undertaking looking at a large number of the most difficult-to-treat patients. CSI is an industry leader in clinical data support for our physician customers, and we're dedicated to providing them with the information they need to make sound treatment decisions for their patients. LIBERTY 360 is the latest example of our commitment to this and we're excited about the data and insight it will provide." The Full Research Report on Cardiovascular Systems Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.wsreports.com/r/full_research_report/1fb2_CSII]

----

EDITOR NOTES:

1. This is not company news. We are an independent source and our views do not reflect the companies mentioned.
2. Information in this release is fact checked and produced on a best efforts basis and reviewed by a CFA. However, we are only human and are prone to make mistakes. If you notice any errors or omissions, please notify us below.
3. This information is submitted as a net-positive to companies mentioned, to increase awareness for mentioned companies to our subscriber base and the investing public.
4. If you wish to have your company covered in more detail by our team, or wish to learn more about our services, please contact us at [email protected].
5. For any urgent concerns or inquires, please contact us at [email protected].
6. Are you a public company? Would you like to see similar coverage on your company? Send us a full investors' package to [email protected] for consideration.

COMPLIANCE PROCEDURE

Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Equity News Network. An outsourced research services provider has, through Chartered Financial Analysts, only reviewed the information provided by Equity News Network in this article or report according to the Procedures outlined by Equity News Network. Equity News Network is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be.

NOT FINANCIAL ADVICE

Equity News Network makes no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise), of the information provided in this document. This information is not to be construed as personal financial advice. Readers are encouraged to consult their personal financial advisor before making any decisions to buy, sell or hold any securities mentioned herein.

NO WARRANTY OR LIABILITY ASSUMED

Equity News Network is not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by Equity News Network whatsoever for any direct, indirect or consequential loss arising from the use of this document. Equity News Network expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Equity News Network does not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.

SOURCE Wall Street Reports